Good_老虎社区_美港股上老虎

Gold75
2021-12-21

Good

BeiGene to receive up to $1 billion in oncology deal with Novartis

BeiGene Ltd. $(BGNE)$ said Monday it had entered an agreement with Swiss drug company Novartis Pharm

BeiGene to receive up to $1 billion in oncology deal with Novartis

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":693676624,"tweetId":"693676624","gmtCreate":1640019492673,"gmtModify":1640019493086,"author":{"id":3576993112269247,"authorId":3576993112269247,"authorIdStr":"3576993112269247","name":"Gold75","avatar":"https://static.tigerbbs.com/3e12eb0f20c1c6eecc3de5d5be4a1184","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":39,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Good&nbsp;</p></body></html>","text":"Good","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/693676624","repostId":2192118114,"repostType":4,"repost":{"id":"2192118114","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1640001240,"share":"https://www.laohu8.com/m/news/2192118114?lang=&edition=full","pubTime":"2021-12-20 19:54","market":"us","language":"en","title":"BeiGene to receive up to $1 billion in oncology deal with Novartis","url":"https://stock-news.laohu8.com/highlight/detail?id=2192118114","media":"Dow Jones","summary":"BeiGene Ltd. $(BGNE)$ said Monday it had entered an agreement with Swiss drug company Novartis Pharm","content":"<p>BeiGene Ltd. <a href=\"https://laohu8.com/S/BGNE\">$(BGNE)$</a> said Monday it had entered an agreement with Swiss drug company Novartis Pharma AG (NOVN.EB) to develop its investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan and to market five Novartis oncology treatments in China. \"Ociperlimab is an investigational potent TIGIT inhibitor with intact Fc function, believed to be critical for the anti-tumor activities of TIGIT antibodies,\" the companies said in a joint statement. Beijing-based BeiGene will receive an upfront payment of $300 million up to $700 million more on exercise by Novartis of a time-based option prior to mid-2023. After that it will be eligible for up to $745 million for reaching certain regulatory milestones, and $1.15 billion for sales milestones and royalties.</p>\n<p>U.S.-listed shares of BeiGene were up 2.3% premarket.</p>\n<p><img src=\"https://static.tigerbbs.com/f9214b86b6b7c704b07a2e7637c99851\" tg-width=\"707\" tg-height=\"603\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeiGene to receive up to $1 billion in oncology deal with Novartis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeiGene to receive up to $1 billion in oncology deal with Novartis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-20 19:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>BeiGene Ltd. <a href=\"https://laohu8.com/S/BGNE\">$(BGNE)$</a> said Monday it had entered an agreement with Swiss drug company Novartis Pharma AG (NOVN.EB) to develop its investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan and to market five Novartis oncology treatments in China. \"Ociperlimab is an investigational potent TIGIT inhibitor with intact Fc function, believed to be critical for the anti-tumor activities of TIGIT antibodies,\" the companies said in a joint statement. Beijing-based BeiGene will receive an upfront payment of $300 million up to $700 million more on exercise by Novartis of a time-based option prior to mid-2023. After that it will be eligible for up to $745 million for reaching certain regulatory milestones, and $1.15 billion for sales milestones and royalties.</p>\n<p>U.S.-listed shares of BeiGene were up 2.3% premarket.</p>\n<p><img src=\"https://static.tigerbbs.com/f9214b86b6b7c704b07a2e7637c99851\" tg-width=\"707\" tg-height=\"603\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","06160":"百济神州","BGNE":"百济神州","NVS":"诺华","BK1161":"生物科技","BK4505":"高瓴资本持仓","BK1500":"做空集合股","BK4139":"生物科技","BK4504":"桥水持仓","BK4526":"热门中概股","BK4007":"制药","BK1583":"高瓴概念","BK4532":"文艺复兴科技持仓","BK1588":"回港中概股"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192118114","content_text":"BeiGene Ltd. $(BGNE)$ said Monday it had entered an agreement with Swiss drug company Novartis Pharma AG (NOVN.EB) to develop its investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan and to market five Novartis oncology treatments in China. \"Ociperlimab is an investigational potent TIGIT inhibitor with intact Fc function, believed to be critical for the anti-tumor activities of TIGIT antibodies,\" the companies said in a joint statement. Beijing-based BeiGene will receive an upfront payment of $300 million up to $700 million more on exercise by Novartis of a time-based option prior to mid-2023. After that it will be eligible for up to $745 million for reaching certain regulatory milestones, and $1.15 billion for sales milestones and royalties.\nU.S.-listed shares of BeiGene were up 2.3% premarket.","news_type":1},"isVote":1,"tweetType":1,"viewCount":453,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}